ALPMF (Astellas Pharma) Tariff Resilience Score: 7/10 (As of Jun. 29, 2026)


ALPMF Astellas Pharma Inc ALPMF
73 GF Score
Price $13.67
GF Value $14.67
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Astellas Pharma Tariff Resilience Score?

Astellas Pharma ALPMF -3.73% 73 Tariff Resilience Score is 7 as of Jun. 29, 2026. GuruFocus rates ALPMF with a GF Score™ of 73/100 and a GF Value™ of $14.67 (Fairly Valued). The stock has 4 warning signs investors should review. Among 1,028 Drug Manufacturers companies, Astellas Pharma ranks better than 97.08% on this metric.

Astellas Pharma has the Tariff Resilience Score of 7, which implies that the company might have Highly Resilient.

Astellas Pharma has Astellas Pharma has moderate tariff exposure, with a strong presence in the U.S. and Japan. The pharmaceutical industry often receives exemptions, and the company has some pricing power. Historical impacts have been manageable.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Astellas Pharma might have Highly Resilient.

Astellas Pharma  (OTCPK:ALPMF) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Astellas Pharma Tariff Resilience Score Related Terms

ALPMF vs LLY, JNJ, ABBV: Tariff Resilience Score Comparison

For the Drug Manufacturers - General subindustry, Astellas Pharma's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Astellas Pharma Tariff Resilience Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Astellas Pharma's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Astellas Pharma's Tariff Resilience Score falls into.


ALPMF
73GF Score
Astellas Pharma Inc ALPMF
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 7 mean?
Astellas Pharma (ALPMF) has a Tariff Resilience Score of 7 as of Jun. 29, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Astellas Pharma ranks #30 out of 1028 companies in the Drug Manufacturers industry, placing it in the top 2.9%.
Is Astellas Pharma's Tariff Resilience Score too high?
Astellas Pharma's current Tariff Resilience Score is 7. Based on the distribution chart, Astellas Pharma ranks #30 out of 1028 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Astellas Pharma has a GF Score™ of 73/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Astellas Pharma's Tariff Resilience Score compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Astellas Pharma ranks #30 out of 1028 companies for Tariff Resilience Score. This places Astellas Pharma in the top 3% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Drug Manufacturers company?
A good Tariff Resilience Score depends on the Drug Manufacturers industry context. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. Astellas Pharma's current Tariff Resilience Score is 7. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Astellas Pharma stock overvalued right now?
Based on GuruFocus' analysis, Astellas Pharma (ALPMF) is currently considered Fairly Valued. The stock's GF Value™ is $14.67, compared to a current price of $13.67 — trading 6.8% below its estimated fair value. The current Tariff Resilience Score is 7. Astellas Pharma's overall GF Score™ is 73/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Astellas Pharma (ALPMF), the current Tariff Resilience Score is 7 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Astellas Pharma (ALPMF) Overvalued in 2026?

Based on GuruFocus' analysis, Astellas Pharma stock appears to be undervalued. The current stock price of $13.67 is trading 6.8% below its estimated GF Value™ of $14.67. GuruFocus considers Astellas Pharma to be Fairly Valued.

Key valuation signals for ALPMF:

  • Tariff Resilience Score: 7
  • GF Value™: $14.67 vs. price of $13.67 (6.8% below fair value)
  • GF Score™: 73/100 with 4 warning signs

No single metric tells the full story. See the ALPMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Astellas Pharma Business Description

Address 2-5-1 Nihonbashi-Honcho, Chuo-ku, Tokyo, JPN, 103-8411
Astellas Pharma Inc is a specialty international pharmaceutical company. The company focuses on accelerating the discovery, development, and commercialization of ground-breaking innovations that could redefine expectations of care for difficult-to-treat diseases. The group is committed to driving innovation in immuno-oncology, gene therapy, mitochondria, blindness and regeneration, and targeted protein degradation. Its core products include anticancer agents like XTANDI, XOSPATA, and PADCEV; VEOZAH for the treatment of vasomotor symptoms due to menopause; Betanis / Myrbetriq / BETMIGA for the treatment of overactive bladder (OAB); and Prograf, an immunosuppressant for organ transplantation.
73GF Score

Get the complete analysis for ALPMF

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.67
Price
$14.67
GF Value